Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy

Trial Profile

Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 May 2018

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Therapeutic Use
  • Sponsors Medifarma
  • Most Recent Events

    • 04 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 04 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 04 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top